Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Exploring optimal therapeutic management of STAGE IA PDAC in the era of neoadjuvant chemotherapy.
Authors
Marina Macchini
Department of Medical Oncology, Pancreas Translational and Clinical Research Centre, Vita -Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy;
Marina Macchini , Giulio Belfiori , Stefano Crippa , Giulia Orsi , Giulia Gasparini , Domenico Tamburrino , Marco Schiavolena , Gabriele Capurso , Massimo Falconi , Michele Reni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 712)
DOI
10.1200/JCO.2023.41.4_suppl.712
Abstract #
712
Poster Bd #
K19
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2023 ASCO Annual Meeting
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.
First Author: Sameer H. Patel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
First Author: Emerson Yu-sheng Chen